TY - JOUR
T1 - Anti–Neutrophil Extracellular Trap Antibodies in Antiphospholipid Antibody–Positive Patients
T2 - Results From the Antiphospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking Clinical Database and Repository
AU - the Antiphospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking
AU - Zuo, Yu
AU - Navaz, Sherwin
AU - Tsodikov, Alex
AU - Kmetova, Katarina
AU - Kluge, Lyndsay
AU - Ambati, Amala
AU - Hoy, Claire K.
AU - Yalavarthi, Srilakshmi
AU - de Andrade, Danieli
AU - Tektonidou, Maria G.
AU - Sciascia, Savino
AU - Pengo, Vittorio
AU - Ruiz-Irastorza, Guillermo
AU - Belmont, H. Michael
AU - Gerosa, Maria
AU - Fortin, Paul R.
AU - de Jesus, Guilherme Ramires
AU - Branch, D. Ware
AU - Andreoli, Laura
AU - Rodriguez-Almaraz, Esther
AU - Petri, Michelle
AU - Cervera, Ricard
AU - Willis, Rohan
AU - Karp, David R.
AU - Li, Quan Zhen
AU - Cohen, Hannah
AU - Bertolaccini, Maria Laura
AU - Erkan, Doruk
AU - Knight, Jason S.
AU - Pons-Estel, Guillermo
AU - Giannakopoulos, Bill
AU - Krilis, Steve
AU - de Jesus, Guilherme
AU - Levy, Roger
AU - Signorelli, Flavio
AU - Andrade, Danieli
AU - Balbi, Gustavo
AU - Clarke, Ann E.
AU - Skeith, Leslie
AU - Fortin, Paul R.
AU - Ji, Lanlan
AU - Zhang, Zhouli
AU - Yang, Chengde
AU - Shi, Hui
AU - Zuily, Stephane
AU - Wahl, Denis
AU - Tektonidou, Maria G.
AU - Nalli, Cecilia
AU - Andreoli, Laura
AU - Gonzalez, Emilio
N1 - Publisher Copyright:
© 2023 The Authors. Arthritis & Rheumatology published by Wiley Periodicals LLC on behalf of American College of Rheumatology.
PY - 2023/8
Y1 - 2023/8
N2 - Objective: This study aimed to elucidate the presence, antigen specificities, and potential clinical associations of anti–neutrophil extracellular trap (anti-NET) antibodies in a multinational cohort of antiphospholipid (aPL) antibody–positive patients who did not have lupus. Methods: Anti-NET IgG/IgM levels were measured in serum samples from 389 aPL-positive patients; 308 patients met the classification criteria for antiphospholipid syndrome. Multivariate logistic regression with best variable model selection was used to determine clinical associations. For a subset of the patients (n = 214), we profiled autoantibodies using an autoantigen microarray platform. Results: We found elevated levels of anti-NET IgG and/or IgM in 45% of the aPL-positive patients. High anti-NET antibody levels are associated with more circulating myeloperoxidase (MPO)–DNA complexes, which are a biomarker of NETs. When considering clinical manifestations, positive anti-NET IgG was associated with lesions affecting the white matter of the brain, even after adjusting for demographic variables and aPL profiles. Anti-NET IgM tracked with complement consumption after controlling for aPL profiles; furthermore, patient serum samples containing high levels of anti-NET IgM efficiently deposited complement C3d on NETs. As determined by autoantigen microarray, positive testing for anti-NET IgG was significantly associated with several autoantibodies, including those recognizing citrullinated histones, heparan sulfate proteoglycan, laminin, MPO–DNA complexes, and nucleosomes. Anti-NET IgM positivity was associated with autoantibodies targeting single-stranded DNA, double-stranded DNA, and proliferating cell nuclear antigen. Conclusion: These data reveal high levels of anti-NET antibodies in 45% of aPL-positive patients, where they potentially activate the complement cascade. While anti-NET IgM may especially recognize DNA in NETs, anti-NET IgG species appear to be more likely to target NET-associated protein antigens.
AB - Objective: This study aimed to elucidate the presence, antigen specificities, and potential clinical associations of anti–neutrophil extracellular trap (anti-NET) antibodies in a multinational cohort of antiphospholipid (aPL) antibody–positive patients who did not have lupus. Methods: Anti-NET IgG/IgM levels were measured in serum samples from 389 aPL-positive patients; 308 patients met the classification criteria for antiphospholipid syndrome. Multivariate logistic regression with best variable model selection was used to determine clinical associations. For a subset of the patients (n = 214), we profiled autoantibodies using an autoantigen microarray platform. Results: We found elevated levels of anti-NET IgG and/or IgM in 45% of the aPL-positive patients. High anti-NET antibody levels are associated with more circulating myeloperoxidase (MPO)–DNA complexes, which are a biomarker of NETs. When considering clinical manifestations, positive anti-NET IgG was associated with lesions affecting the white matter of the brain, even after adjusting for demographic variables and aPL profiles. Anti-NET IgM tracked with complement consumption after controlling for aPL profiles; furthermore, patient serum samples containing high levels of anti-NET IgM efficiently deposited complement C3d on NETs. As determined by autoantigen microarray, positive testing for anti-NET IgG was significantly associated with several autoantibodies, including those recognizing citrullinated histones, heparan sulfate proteoglycan, laminin, MPO–DNA complexes, and nucleosomes. Anti-NET IgM positivity was associated with autoantibodies targeting single-stranded DNA, double-stranded DNA, and proliferating cell nuclear antigen. Conclusion: These data reveal high levels of anti-NET antibodies in 45% of aPL-positive patients, where they potentially activate the complement cascade. While anti-NET IgM may especially recognize DNA in NETs, anti-NET IgG species appear to be more likely to target NET-associated protein antigens.
UR - http://www.scopus.com/inward/record.url?scp=85159683587&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85159683587&partnerID=8YFLogxK
U2 - 10.1002/art.42489
DO - 10.1002/art.42489
M3 - Article
C2 - 36862141
AN - SCOPUS:85159683587
SN - 2326-5191
VL - 75
SP - 1407
EP - 1414
JO - Arthritis and Rheumatology
JF - Arthritis and Rheumatology
IS - 8
ER -